ACT Capital is pleased to offer for acquisition a highly profitable, very high growth, medical technology company. The Company’s core business is advancing the art of aesthetic and regenerative injectables. It designs, patents, and manufactures proprietary medical products for the harvesting, processing, and deployment of FDA 361 and FDA 510(k) compliant autologous soft tissue. Over 300 doctors are using the products in the fields of aesthetic and cosmetic surgery applications, regenerative medicine including orthopedic surgery, pain management, and anti-aging procedures.

The Company has experienced 15 – 25% EBITDA margins for the last five years, with this year expected to be on the same track.  2026 should experience significant growth as a new 5 year minimum contract with a national medical center operator begins, which is expected to add $1.5M+ in revenue each year with $500K+ in additional EBITDA on top of the continuing existing business.